Mammogram Sensitivity Varies by Week of Menstrual Cycle
Premenopausal women who schedule regular mammograms may benefit by undergoing screening during the first week of their menstrual cycle, according to research published in the February issue of Radiology.
WEDNESDAY, Feb. 16 (HealthDay News) -- Premenopausal women who schedule regular mammograms may benefit by undergoing screening during the first week of their menstrual cycle, according to research published in the February issue of Radiology.
Diana L. Miglioretti, Ph.D., of the Group Health Cooperative in Seattle, and colleagues studied data on 387,218 screening mammograms linked to 1,283 breast cancers in premenopausal women to investigate the effectiveness of screening mammography by week of the menstrual cycle.
The researchers found little overall difference in mammography performance according to week of menstrual cycle, but further analysis reveled greater sensitivity in week one in the 66.6 percent of women who had undergone regular screening mammography (sensitivity of 79.5, 70.3, 67.4, and 73.0 percent in weeks one, two, three, and four, respectively). Sensitivity tended to be lower in week one, however, in the 17.8 percent of women receiving a first-time mammogram (P = .051).
"Premenopausal women who undergo regular screening may benefit from higher sensitivity of mammography if they schedule screening mammography during the first week of their menstrual cycle," the authors write.
AbstractFull Text (subscription or payment may be required)
Related Content
- OBGYN.netBreast Care
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More
